Stock News & Analysis

Boston Properties leads the U.S. in Class A office ownership, managing over 51 million square feet across top urban markets.

Veteran investors knew this reality check of extreme valuations was coming sometime.

RLJ Lodging Trust operates a portfolio of premium-branded hotels, emphasizing high-margin, select-service properties.

Is Amcor's 5.3% dividend yield and recent profit surge a reason to buy, or is it just another value trap? Here's what income investors need to know.

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Super Micro advances after pointing to at least $40 billion in full-year revenue following record quarterly results tied to AI systems. The stock’s sharp jump puts the spotlight on whether the company can keep converting that demand into stronger margins.

Today, Feb. 19, 2026, investors confront Klarna’s record revenue colliding with rising credit costs and softer guidance.

Today, Feb. 19, 2026, Walmart’s cautious outlook rattled U.S. stocks as investors weighed fading rate-cut hopes and rising geopolitical risk.

Western Union stock trades at what appears to be an attractive price, but there's a reason for that.

It's getting more expensive for the company to retain medical professionals.

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Viavi Solutions, a leader in network testing and security, saw a key insider trim their stake amid strong one-year stock gains.

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Marvell is executing in AI, but its valuation leaves no room for mistakes. Here is what must happen next for real upside.

These artificial intelligence (AI) stocks show promising upside for long-term investors.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Investors weigh booming online sales against cautious profit guidance and fresh shareholder-return moves, today, Feb. 19, 2026.

Hess Midstream has long been viewed as a steady income name in energy. Investors may want to watch its distribution coverage and debt levels to assess whether that stability remains intact.

Yes, there are bargains out there for investors seeking income-paying stocks.